Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

Anthonisen, Nicholas R.

doi:10.1001/jama.272.19.1497

Cited by 811 publications

(711 citation statements)

References 0 publications

Supporting

Mentioning

630

Contrasting

Unclassified

Order By: Relevance

“…Supplemental Figure 4 summarizes the depth of coverage for the coding and exon-flanking sequences of the candidate genes. The COPDGene subjects who underwent exome sequencing (total n = 415) were smokers who were selected for extreme phenotypes (33). Case subjects were selected to enrich for a severe, early-onset phenotype: younger than 63 years, with severe or very severe obstruction (FEV 1 less than 50% of predicted values), and greater than 15% emphysema on CT scan (n = 209) (32).…”

Section: Discussionmentioning

confidence: 99%

Telomerase mutations in smokers with severe emphysema

Stanley¹,

Chen²,

Podlevsky³

et al. 2014

J. Clin. Invest.

162

140

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Telomerase mutations in smokers with severe emphysema

Stanley¹,

Chen²,

Podlevsky³

et al. 2014

J. Clin. Invest.

162

140

View full text Add to dashboard Cite

“…This is in contrast to coronary artery disease, where despite the fact that cigarette smoking is a major risk factor (47), none of the identified genome-wide association loci to date has identified variants known to affect smoking, and a minority of the identified loci have been associated with traditional risk factors (48). Ongoing cigarette smoking causes accelerated lung function decline; conversely, smoking cessation attenuates this decline, improves respiratory symptoms and reduces overall mortality (49)(50)(51)(52). Decreasing cigarette consumption is essential to reducing the risk of COPD, and though a subset of our subjects carry lower risk alleles, our data do not suggest that there are smokers unlikely to benefit from smoking cessation.…”

Section: Discussionmentioning

confidence: 99%

A Genome-Wide Association Study In COPD Identifies A Susceptibility Locus On Chromosome 19q13

Cho

Castaldi

Hersh

et al. 2011

A95. Cutting Edge Insights to the Pathobiology of Copd and Interstitial Lung Disease

View full text Add to dashboard Cite

The genetic risk factors for chronic obstructive pulmonary disease (COPD) are still largely unknown. To date, genome-wide association studies (GWASs) of limited size have identified several novel risk loci for COPD at CHRNA3/CHRNA5/IREB2, HHIP and FAM13A; additional loci may be identified through larger studies. We performed a GWAS using a total of 3499 cases and 1922 control subjects from four cohorts: the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE); the Normative Aging Study (NAS) and National Emphysema Treatment Trial (NETT); Bergen, Norway (GenKOLS); and the COPDGene study. Genotyping was performed on Illumina platforms with additional markers imputed using 1000 Genomes data; results were summarized using fixed-effect meta-analysis. We identified a new genomewide significant locus on chromosome 19q13 (rs7937, OR 5 0.74, P 5 2.9 3 10 29 ). Genotyping this single * Molecular Genetics, 2012, Vol. 21, No. 4 947-957 doi:10.1093/hmg/ddr524 Advance Access published on November 11, 2011nucleotide polymorphism (SNP) and another nearby SNP in linkage disequilibrium (rs2604894) in 2859 subjects from the family-based International COPD Genetics Network study (ICGN) demonstrated supportive evidence for association for COPD (P 5 0.28 and 0.11 for rs7937 and rs2604894), pre-bronchodilator FEV 1 (P 5 0.08 and 0.04) and severe (GOLD 3&4) COPD (P 5 0.09 and 0.017). This region includes RAB4B, EGLN2, MIA and CYP2A6, and has previously been identified in association with cigarette smoking behavior.

show abstract

“…Stopping smoking is the only intervention that will slow the rate of progression of COPD and prolong life expectancy [7] *** . It will reduce the rate of decline in lung function to that of a nonsmoker in most patients who stop smoking.…”

Section: Smoking Cessationmentioning

confidence: 99%

International Primary Care Respiratory Group (IPCRG) Guidelines: Management of Chronic Obstructive Pulmonary Disease (COPD)

Bellamy¹,

Bouchard

Henrichsen

et al. 2006

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Summary COPD is a common and under-diagnosed disease which is increasing in prevalence worldwide. A more aggressive and optimistic approach must be adopted towards its management in primary care. This IPCRG Guideline on the management of COPD in primary care is fully consistent with GOLD guidelines. It highlights the goals of COPD treatment and the need for spirometric testing to make the diagnosis. It covers the classification of the disease according to disease severity, non-pharmacologic therapy including smoking cessation, avoidance of risk factors, patient education, pharmacologic therapy including the use of oxygen treatment, the management of exacerbations, the role of pulmonary rehabilitation, and the need for monitoring and ongoing care for COPD patients.

show abstract

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

Cited by 811 publications

References 0 publications

Telomerase mutations in smokers with severe emphysema

Telomerase mutations in smokers with severe emphysema

A Genome-Wide Association Study In COPD Identifies A Susceptibility Locus On Chromosome 19q13

International Primary Care Respiratory Group (IPCRG) Guidelines: Management of Chronic Obstructive Pulmonary Disease (COPD)

Contact Info

Product

Resources

About